An observational study in Lenses, Intraocular and Glaucoma Filtration Implants, sponsored by Clínica Rementería. Status unknown at 1 site in Spain. Open to participants aged 40 Years to 95 Years. Per ClinicalTrials.gov, last updated 2022-07-20.
Sponsored by Clínica Rementería · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies in Glaucoma with a site in Spain — 7 open to participants now, 7 under way, none of them phase 3. Glaucoma · Spain.
Among the 43 studies in Glaucoma with a site in Spain, this one is the 8th largest by planned enrollment of the 10 observational ones that give a count, is one of 2 that started in 2022, is one of 10 observational ones, and was the 34th registered.
1,421 studies on the registry are indexed under Glaucoma; 221 are open to participants now.
Browse Glaucoma studies →7 of the 43 studies in Glaucoma with a site in Spain are open now. Recruiting first, the newest first:
Institut Catala de Retina · Sites in Spain
Ages 50–75
Clínica Rementería · Sites in Spain
Ages 18+
Fundacio Privada Mon Clinic Barcelona · Sites in Spain
Ages 18+
Hospital Clinic of Barcelona · Sites in Spain
Ages 40–80 · Healthy volunteers
Barbara Burgos Blasco · Sites in Spain
Ages 18+
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 154 Glaucoma studies recruiting now, 112 (73%) set no upper age limit and 9 (6%) stop at 75 or younger; 13 take children under 18; 44 take healthy volunteers.
This study: 40 Years to 95 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 3 · Phase 3 4 · Phase 4 8
First in 2003; this study’s year is marked. 2 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 45 is below the median of 101 across 386 observational studies indexed under Glaucoma.
Median enrollment 100 across the 33 interventional studies, 365 across the 10 observational. Of the 32 that completed or were terminated, 8 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 43 have an industry lead sponsor. The 10 most frequent:
Clínica Rementería is the lead sponsor of 5 studies on the registry; 1 is open to participants now.
Clínica Rementería has 2 studies filed under Glaucoma — fewer than ten, so there is no comparison to draw.
1 of the studies in Glaucoma with a site in Spain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07322965Institut Catala de RetinaEvaluation of BRUDYGLAUCO (DHA + Citicoline) in Patients With Glaucoma | 2027-04-30 |
Add it to your calendar (.ics) → With an account.
Among the 43 studies in Glaucoma with a site in Spain, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
New extended depth of focus intraocular lenses (IOLs) are being used in a broader spectrum of patients than trifocal IOLs. The purpose of this study is to evaluate visual improvement after cataract surgery in patients with glaucoma or ocular hypertension undergoing simultaneous cataract surgery with i-Stent implantation with the implantation of a Vivity IOL. Results will be compared with a group of glaucoma or ocular hypertension undergoing isolated cataract surgery with Vivity implantation, as well as with patients with no pathology undergoing cataract surgery and Vivity implantation
The purpose of this study is to report in detail visual function and patient satisfaction, as well as the need for spectacle correction, in patients with glaucoma and ocular hypertension undergoing cataract surgery with bilateral implantation of an extended depth of focus IOL, the Vivity IOL. The study also seeks to determine if there are differences in the speed of visual improvement between patients undergoing isolated cataract surgery and patients undergoing simultaneous i-Stent implantation. Results will also be compared with a group of patients with no ocular pathology undergoing cataract surgery with Vivity implantation.
Patients will be asked to join the study once the type of surgery (isolated phacoemulsification versus phacoemulsification combined with i-Stent implantation) and the type of lens to be implanted (monofocal, EDoF, trifocal) has been agreed between ophthalmologist and patient. Therefore, inclusion in the study will have no influence on surgical indication.
Once informed consent has been signed, the patient will be included in the study.
Explorations specific for the study will be performed 3 and 12 months after surgery and include:
Defocus curves Contrast sensitivity Self-reported photic phenomena Need for spectacle correction Satisfaction measured with the Catquest SF9 questionnaire
Besides study-specific procedures, the following explorations which are standard of care will be performed one day, one week and one month after surgery:
Uncorrected binocular visual acuity for distance, intermediate and near distances Monocular distance corrected and uncorrected visual acuity Residual subjective refraction Slit-lamp examination Intraocular pressure and number of hypotensive drugs required Description of any intra- or postsurgical complications
Patients with glaucoma or ocular hypertension or healthy subjects undergoing bilateral cataract surgery with Vivity intraocular lens implantation with or without i-Stent implantation
Inclusion Criteria: Bilateral cataract surgery with Vivity implantation with or without i_STent implantation
Exclusion Criteria: Ocular disease other than glaucoma
Patients with Glaucoma or Ocular Hypertension undergoing simultaneous cataract and i-Stent implantation, with Vivity intraocular lens
Device: I-Stent implantation
Patients with Glaucoma or Ocular Hypertension undergoing isolated phacoemulsification with Vivity intraocular lens
Patients with undergoing isolated phacoemulsification with Vivity intraocular lens
I-Stent implantation
Binocular uncorrected distance visual acuity
Binocular uncorrected distance visual acuity
Time frame: Three months after surgery
Binocular uncorrected intermediate visual acuity
Binocular uncorrected intermediate visual acuity
Time frame: Three months after surgery
Binocular uncorrected near visual acuity
Binocular uncorrected near visual acuity
Time frame: Three months after surgery
Binocular uncorrected distance visual acuity
Binocular uncorrected distance visual acuity
Time frame: One month after surgery
Binocular uncorrected intermediate visual acuity
Binocular uncorrected intermediate visual acuity
Time frame: One month after surgery
Binocular uncorrected near visual acuity
Binocular uncorrected near visual acuity
Time frame: One month after surgery
Contrast sensitivity
Contrast sensitivity
Time frame: Three months after surgery
Need for spectacle correction
Need for spectacle correction
Time frame: Three months after surgery
Patient satisfaction
Patient satisfaction evaluated with the Catquest SF9 questionnaire
Time frame: Three months after surgery
Plan to share: Undecided
No publications or documents are linked to this record.
Started Jun 2022 (actual). Primary completion is estimated for Jun 2024, 24 months after the start.
Of 111 non-industry observational studies under Glaucoma, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 208. This study's planned 24 months is below that.
Counting every sponsor, half of 135 studies reached it within 31 months; a quarter within 11 and three quarters within 208.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Clínica Rementería